Retatrutide is a novel anti-obesity peptide known as a GGG tri-agonist, targeting three key receptors: GLP-1, GIP, and glucagon. This unique mechanism allows it to significantly reduce appetite, delay gastric emptying, and enhance energy expenditure—making it highly effective for weight loss. In clinical trials, retatrutide has demonstrated body weight reductions of up to 24%, outperforming other incretin-based therapies like semaglutide and tirzepatide. Its extended half-life supports convenient once-weekly dosing. In addition to weight loss, retatrutide shows promise in lowering blood sugar (HbA1c), improving metabolic health, and potentially offering cardiovascular benefits.
